GLP-1受体激动剂与二甲双胍治疗多囊卵巢综合征的比较:系统综述与Meta分析
本Meta分析纳入8项随机对照试验,比较GLP-1受体激动剂与二甲双胍对多囊卵巢综合征患者的疗效。结果显示GLP-1受体激动剂在改善胰岛素敏感性、降低体质指数和腹围方面优于二甲双胍,但恶心和头痛发生率更高。作者认为GLP-1受体激动剂可能是肥胖伴胰岛素抵抗的PCOS患者的选择,但现有证据质量中至低,结论不确定。
要点
- 与二甲双胍相比,GLP-1受体激动剂改善胰岛素敏感性更有效(SMD -0.40,95%CI -0.74至-0.06,P=0.02)。
- GLP-1受体激动剂降低体质指数(SMD -1.02,95%CI -1.85至-0.19,P=0.02)和腹围(SMD -0.45,95%CI -0.89至-0.00,P=0.05)优于二甲双胍。
- GLP-1受体激动剂恶心和头痛发生率高于二甲双胍,其他数据无显著差异。
核心结论
- 与二甲双胍相比,GLP-1受体激动剂可能是肥胖PCOS患者尤其是伴胰岛素抵抗者的良好选择。
- 现有证据质量中至低,结论不确定,需要更多高质量研究评估GLP-1受体激动剂对PCOS女性的疗效。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、EMBASE、Cochrane Library、万方数据库、CNKI从建库至2018年6月的文献。
- 纳入8项比较GLP-1受体激动剂与二甲双胍治疗PCOS的随机对照试验,共462篇相关文献。
主要发现
- 与二甲双胍相比,GLP-1受体激动剂改善胰岛素敏感性更有效(SMD -0.40,95%CI -0.74至-0.06,P=0.02)。
- 与二甲双胍相比,GLP-1受体激动剂降低体质指数更有效(SMD -1.02,95%CI -1.85至-0.19,P=0.02)。
- 与二甲双胍相比,GLP-1受体激动剂降低腹围更有效(SMD -0.45,95%CI -0.89至-0.00,P=0.05)。
- GLP-1受体激动剂恶心和头痛发生率高于二甲双胍,其他数据无显著差异。
临床怎么用
- 作者认为,与二甲双胍相比,GLP-1受体激动剂可能是肥胖PCOS患者尤其是伴胰岛素抵抗者的良好选择。
- 作者指出现有证据质量中至低,结论不确定,需要更多高质量研究评估GLP-1受体激动剂对PCOS女性的疗效。
局限性
- 现有证据质量中至低,结论不确定。
- 需要更多高质量研究评估GLP-1受体激动剂对PCOS女性的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This meta-analysis aimed to evaluate the efficacy and safety of glucagon-like peptide 1 (GLP-1) receptor agonists for women with polycystic ovary syndrome (PCOS) by comparing their effect with that of metformin. Electronic databases (PubMed, EMBASE, Cochrane Library, WanFang Database, CNKI) dating from their establishment to June 2018 were searched to find all randomized controlled trials (RCTs) reporting the efficacy of GLP-1 receptor agonists versus metformin for patients with PCOS. Therapeutic variables included menstrual cycle, sex hormone and clinical manifestations, glucose metabolism and other metabolic indexes. Eight RCTs among 462 related articles were included in the meta-analysis. Compared with metformin, GLP-1 receptor agonists were more effective in improving insulin sensitivity (standard mean difference [SMD] -0.40, 95% confidence interval [CI] -0.74 to -0.06, P = 0.02) and reducing body mass index (SMD -1.02, 95% CI -1.85 to -0.19, P = 0.02) and abdominal girth (SMD -0.45, 95% CI -0.89 to -0.00, P = 0.05). GLP-1 receptor agonists were associated with a higher incidence of nausea and headache than metformin, but there were no significant differences in other data. Therefore, compared with metformin, GLP-1 receptor agonists might be a good choice for obese patients with PCOS, especially those with insulin resistance. The available evidence is, however, inconclusive given its moderate to low quality. More high-quality research is needed to assess the efficacy of a GLP-1 receptor agonist on women with PCOS.
引用
- Han Y, Li Y, He B, et al. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. Reprod Biomed Online. 2019. PMID: 31229399. doi:10.1016/j.rbmo.2019.04.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。